[go: up one dir, main page]

AR115722A1 - Método para prevenir o tratar neuropatías periféricas o dolores asociados con enfermedades que tienen neuropatías periféricas o daños astrocíticos - Google Patents

Método para prevenir o tratar neuropatías periféricas o dolores asociados con enfermedades que tienen neuropatías periféricas o daños astrocíticos

Info

Publication number
AR115722A1
AR115722A1 ARP190101933A ARP190101933A AR115722A1 AR 115722 A1 AR115722 A1 AR 115722A1 AR P190101933 A ARP190101933 A AR P190101933A AR P190101933 A ARP190101933 A AR P190101933A AR 115722 A1 AR115722 A1 AR 115722A1
Authority
AR
Argentina
Prior art keywords
peripheral neuropathies
preventing
treating
rgma
agent
Prior art date
Application number
ARP190101933A
Other languages
English (en)
Inventor
Atsushi Sasaki
Joseph M Palumbo
Hirokazu Ishida
Hayato Ishida
Original Assignee
Mitsubishi Tanabe Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Tanabe Pharma Corp filed Critical Mitsubishi Tanabe Pharma Corp
Publication of AR115722A1 publication Critical patent/AR115722A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente provee métodos para prevenir o tratar neuropatías periféricas y para prevenir o tratar síntomas de dolor asociados con enfermedades que tienen neuropatías periféricas o daños astrocíticos, y también provee un agente para prevenir o tratar neuropatías periféricas o síntomas de dolor asociados con enfermedades que tienen neuropatías periféricas o daños astrocíticos, en donde el agente contiene una sustancia inhibidora de RGM. Reivindicación 1: Un agente para prevenir o tratar una neuropatía periférica, caracterizado porque el agente comprende una sustancia inhibidora de RGM. Reivindicación 2: El agente de acuerdo a la reivindicación 1, caracterizado porque la sustancia inhibidora de RGM es una sustancia inhibidora de RGMa. Reivindicación 3: El agente de acuerdo a la reivindicación 2, caracterizado porque la sustancia inhibidora de RGMa es un anticuerpo neutralizante anti-RGMa o un fragmento del mismo. Reivindicación 4: El agente de acuerdo a la reivindicación 3, caracterizado porque el anticuerpo neutralizante anti-RGMa es un anticuerpo humanizado. Reivindicación 15: Un método para prevenir o tratar una neuropatía periférica, caracterizado porque comprende administrar una cantidad eficaz de una sustancia inhibidora anti-RGMa a un mamífero que lo necesite.
ARP190101933A 2018-07-10 2019-07-10 Método para prevenir o tratar neuropatías periféricas o dolores asociados con enfermedades que tienen neuropatías periféricas o daños astrocíticos AR115722A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862696052P 2018-07-10 2018-07-10

Publications (1)

Publication Number Publication Date
AR115722A1 true AR115722A1 (es) 2021-02-17

Family

ID=69142006

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP190101933A AR115722A1 (es) 2018-07-10 2019-07-10 Método para prevenir o tratar neuropatías periféricas o dolores asociados con enfermedades que tienen neuropatías periféricas o daños astrocíticos

Country Status (15)

Country Link
US (1) US20210269516A1 (es)
EP (1) EP3821908A4 (es)
JP (2) JP7449859B2 (es)
KR (2) KR20240163200A (es)
CN (4) CN112533635A (es)
AR (1) AR115722A1 (es)
AU (2) AU2019301336B2 (es)
BR (1) BR112021000300A2 (es)
CA (1) CA3106074A1 (es)
IL (1) IL280018A (es)
MX (1) MX2021000324A (es)
PH (1) PH12021550055A1 (es)
SG (1) SG11202100235YA (es)
TW (1) TW202019481A (es)
WO (1) WO2020013238A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR120898A1 (es) * 2019-12-26 2022-03-30 Univ Osaka Agente para tratar o prevenir neuromielitis óptica en fase aguda
IL294769A (en) * 2020-01-15 2022-09-01 Univ Osaka rgma suppressing substances for use in the treatment of dementia
JP7698842B2 (ja) * 2020-01-15 2025-06-26 国立大学法人大阪大学 糖尿病性自律神経障害の予防又は治療剤
WO2023081458A1 (en) * 2021-11-08 2023-05-11 Rutgers, The State University Of New Jersey Systems and methods for diagnosis and/or treating demyelinating neuropathy

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
DK0463151T3 (da) 1990-01-12 1996-07-01 Cell Genesys Inc Frembringelse af xenogene antistoffer
JP2938569B2 (ja) 1990-08-29 1999-08-23 ジェンファーム インターナショナル，インコーポレイティド 異種免疫グロブリンを作る方法及びトランスジェニックマウス
EP0652950B1 (en) 1992-07-24 2007-12-19 Amgen Fremont Inc. Generation of xenogeneic antibodies
CA2161351C (en) 1993-04-26 2010-12-21 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
JP4986370B2 (ja) * 2000-12-22 2012-07-25 マックス−プランク−ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ Ｒｇｍおよびそのモジュレーターの用途
US20030236477A1 (en) * 2002-06-25 2003-12-25 Huang Chu Chau Massage device
US20070253946A1 (en) 2004-03-11 2007-11-01 Bioclues, Inc. Axon Regeneration Promoter
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
ES2562832T3 (es) * 2009-12-08 2016-03-08 Abbvie Deutschland Gmbh & Co Kg Anticuerpos monoclonales contra la proteína RGM para su uso en el tratamiento de la degeneración de la capa de fibra nerviosa de la retina
WO2012047706A2 (en) * 2010-10-06 2012-04-12 Massachusetts Eye & Ear Infirmary Methods for promotiing reinnervation of auditory hair cells
MY194587A (en) * 2012-01-27 2022-12-05 Abbvie Inc Composition and method for the diagnosis and treatment of diseases associated with neurite degeneration
IL287291B (en) 2015-04-28 2022-09-01 Univ Osaka A protein that binds to rgma and its use
EP3464372A1 (en) * 2016-06-01 2019-04-10 AbbVie Inc. Anti-repulsive guidance molecule a (rgma) antagonistic antibodies for treating spinal cord injury and pain

Also Published As

Publication number Publication date
CA3106074A1 (en) 2020-01-16
IL280018A (en) 2021-03-01
PH12021550055A1 (en) 2021-11-08
KR20240163200A (ko) 2024-11-18
AU2023200728A1 (en) 2023-03-16
JP2024026683A (ja) 2024-02-28
JP7449859B2 (ja) 2024-03-14
CN112533635A (zh) 2021-03-19
BR112021000300A2 (pt) 2021-04-06
AU2019301336B2 (en) 2022-11-24
WO2020013238A1 (ja) 2020-01-16
EP3821908A4 (en) 2022-03-30
KR20210032412A (ko) 2021-03-24
AU2023200728B2 (en) 2025-10-02
KR102731135B1 (ko) 2024-11-15
SG11202100235YA (en) 2021-02-25
EP3821908A1 (en) 2021-05-19
JP7742433B2 (ja) 2025-09-19
CN117919419A (zh) 2024-04-26
US20210269516A1 (en) 2021-09-02
CN117919420A (zh) 2024-04-26
AU2019301336A1 (en) 2021-02-11
MX2021000324A (es) 2021-03-25
TW202019481A (zh) 2020-06-01
JPWO2020013238A1 (ja) 2021-07-15
CN117919418A (zh) 2024-04-26

Similar Documents

Publication Publication Date Title
AR115722A1 (es) Método para prevenir o tratar neuropatías periféricas o dolores asociados con enfermedades que tienen neuropatías periféricas o daños astrocíticos
CL2021002966A1 (es) Combinación de inhibidores de pd-1 e inhibidores de lag-3 para mejorar la eficacia en el tratamiento del cancer.
CL2021002267A1 (es) Métodos para tratar cánceres y potenciar la eficacia de agentes terapéuticos para el redireccionamiento de células t. (divisional de solicitud 202002945)
MX2018013848A (es) Combinacion de anticuerpos anti-pd-1s y radiacion para tratar cancer.
CL2021002533A1 (es) Composiciones y métodos para el tratamiento de enfermedades o trastornos asociados con kras
CR20190162A (es) Métodos para usar un anticuerpo biespecífico que reconoce el factor de coagulación ix y/o el factor de coagulación ix activado y el factor de coagulación x y/o el factor de coagulación x activado
EA202191185A1 (ru) Способы ингибирования ангиогенеза у пациента
MX2019009772A (es) Anticuerpos anti-pd-1 para el tratamiento del cancer de pulmon.
BR112023000687A2 (pt) Métodos e combinações de inibidores de kat6 para o tratamento de câncer
CL2023002746A1 (es) Inhibidores de la línea 1 para tratar enfermedades del snc y sistémicas
MX376077B (es) Tratamiento de una disfuncion cardiaca diastolica con un agonista del receptor trpv2.
MX2021000516A (es) Composicion farmaceutica para usarse en el tratamiento o prevencion de una enfermedad relacionada con c5 y metodo para tratar o prevenir una enfermedad relacionada con c5.
MX387658B (es) Métodos para tratar y/o prevenir queratosis actínica.
CL2022003511A1 (es) Inhibidores de alk2 para el tratamiento de la anemia.
AR107983A1 (es) Métodos para tratar eventos adversos gastrointestinales relacionados con el sistema inmunitario en tratamientos de combinación anti-ctla4 anti-pd-1
AR107893A1 (es) TERAPIAS COMBINADAS, COMBINACIÓN DE UN INHIBIDOR DE BACE Y UN ANTICUERPO O UN FRAGMENTO DE UNIÓN AL ANTÍGENO PARA EL TRATAMIENTO DE UN TRASTORNO ASOCIADO CON LA ACUMULACIÓN DE b AMILOIDE
CL2022000214A1 (es) Inhibidores de enzimas
BR112019011350A2 (pt) terapia de combinação
PE20241351A1 (es) Formulacion farmaceutica que comprende el anticuerpo monoclonal anti-ox40
MX2025012459A (es) Métodos para tratar el mieloma múltiple
MX2021002761A (es) Metodos para tratar la pancreatitis.
MX2021002590A (es) Metodos de uso de un compuesto de fenoxipropilamina para tratar el dolor.
MX2024011916A (es) Inhibidores de retrotransposones del elemento 1 intercalado largo (line-1) tipo nucleosido
MX2019006013A (es) Composicion farmaceutica para evitar la adiccion a opioides.
CL2024001421A1 (es) Uso de composición que comprende un anticuerpo anti masp-2 para tratar síndrome de neumonìa idiopàtica.